Document is current
Any future updates will be listed below
-
Authors
Boertien, Jeffrey M. https://orcid.org/0000-0002-9664-1771
Murtomäki, Kirsi
Pereira, Pedro A. B.
van der Zee, Sygrid
Mertsalmi, Tuomas H.
Levo, Reeta https://orcid.org/0000-0003-4481-1254
Nojonen, Tanja
Mäkinen, Elina
Jaakkola, Elina
Laine, Pia
Paulin, Lars https://orcid.org/0000-0003-0923-1254
Pekkonen, Eero https://orcid.org/0000-0003-1621-8752
Kaasinen, Valtteri https://orcid.org/0000-0002-3446-7093
Auvinen, Petri https://orcid.org/0000-0002-3947-4778
Scheperjans, Filip https://orcid.org/0000-0001-9502-7131
van Laar, Teus
,
Verwey, N. A.
van Harten, B.
Portman, A. T.
Langedijk, M. J. H.
Oomes, P. G.
Jansen, B. J. A. M.
van Wieren, T.
van den Bogaard, S. J. A.
van Steenbergen, W.
Duyff, R.
van Amerongen, J. P.
Fransen, P. S. S.
Polman, S. K. L.
Zwartbol, R. T.
van Kesteren, M. E.
Braakhekke, J. P.
Trip, J.
Koops, L.
de Langen, C. J.
de Jong, G.
Hartono, J. E. S.
Ybema, H.
Bartels, A. L.
Reesink, F. E.
Postma, A. G.
Vonk, G. J. H.
Oen, J. M. T. H.
Brinkman, M. J.
Mondria, T.
Holscher, R. S.
van der Meulen, A. A. E.
Rutgers, A. W. F.
Boekestein, W. A.
Teune, L. K.
Orsel, P. J. L.
Hoogendijk, J. E.
van Laar, T.
- License Information
-
More Information
Article History
Received: 17 February 2022
Accepted: 14 September 2022
First Online: 10 October 2022
Competing interests
: J.M.B. received an honorarium for writing an article for the magazine “Kinetic” by Britannia Pharmaceuticals and owns exchange traded funds that might include stocks in medically related fields. K.M. grants from The Finnish Parkinson Foundation, Hospital District of Helsinki and Uusimaa and Maire Taponen Foundation. E.J. has received a grant from the Finnish Parkinson Foundation. E.P. has received consulting fees from Abbvie, Boston Scientific, Nordic Infucare and is consulting neurologist for patient insurance center of Finland. Speaker’s honoraria from Abbott, Abbvie, and Nordic InfuCare. He is PI in Finland: International Adroit-study (Abbott DBS Registry of Outcomes for Indications over Time) 2021: Organized by Abbott. VK received consulting fees from Orion Pharma and Nordic Infucare AB, participated in advisory boards for Abbvie and Nordic Infucare AB, and received speaker’s honoraria from Nordic Infucare AB, GE Healthcare and Abbvie. F.S. has received grants from The Academy of Finland, The Hospital District of Helsinki and Uusimaa, OLVI-Foundation, Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse, The Wilhelm and Else Stockmann Foundation, The Emil Aaltonen Foundation, The Yrjö Jahnsson Foundation, Renishaw, and honoraria from AbbVie, Orion, GE Healthcare, Merck, Teva, Bristol Myers Squibb, Sanofi, and Biogen. F.S. is the founder and CEO of NeuroInnovation Oy and NeuroBiome Ltd., is a member of the scientific advisory board and has received consulting fees and stock options from Axial Biotherapeutics. T.v.L. has received grant support from the MJFF, the UMCG, Menzis, Weston Brain Institute, and the Dutch Brain Foundation. Consultancy fees were received from AbbVie, Britannia Pharm., Centrapharm and Neuroderm. Speaker fees were received from AbbVie, Britannia Pharm., and Eurocept. P.A.B.P., L.P., P.A., and F.S. have patents issued (FI127671B & US10139408B2) and pending (US16/186,663 & EP3149205) that are assigned to NeuroBiome Ltd. Non-financial competing interests: E.P. is a member of the MDS Non-Motor Study Group. All other authors declare to have no non-financial competing interests.
